This volume reviews advances in cancer chemotherapy research over the last 10 years and will be of interest to scientists engaged in drug research in the pharmaceutical industry, biotechnology and startup companies, academia and government institutions. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs, including anti-hormonal therapy, growth factor inhibition, survival signaling, cell cycle inhibition, anti-angiogenics and anti-invasives. Each chapter covers the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.

In each volume an overview chapter introduces the newcomer to the topic covered Series covers hot topics of frontier research summarized by reputed scientists in the field Review series is topic related Online version available on SpringerLink: springerlink.com

Inhalt
Overview.- Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer.- Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK.- Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic.- Survival Signaling.- Progress in the Development of Agents to Control the Cell Cycle.- HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit.- Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy.- Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy.- Bcr-Abl Kinase Inhibitors.